Abstract
GABAB receptors are heterodimers of two subunits, GABAB1 (GB1) and GABAB2 (GB2). Agonists such as GABA and baclofen bind to the GB1 subunit only, whereas GB2 is essential for G protein activation. Positive allosteric modulators enhance the potency and efficacy of agonists at GABAB receptors and are of particular interest because they lack the sedative and muscle relaxant properties of agonists. In this study, we aimed to characterize the interaction of the positive modulator N,N′-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine (GS39783) with the GABAB receptor heterodimer. Using functional guanosine 5′-O-(3-[35S]thio)triphosphate binding assays, we observed positive modulation by GS39783 in different vertebrate species but not in Drosophila melanogaster. However, coexpression of D. melanogaster GB1 with rat GB2 yielded functional receptors positively modulated by GS39783. Together with data from rat/D. melanogaster GB2 subunit chimeras, this pointed to a critical role of the GB2 transmembrane region for positive modulation. We further characterized GS39783 function using point mutations. GS39783 positively modulated GABA responses but also showed considerable agonistic activity at heterodimers containing a mutant rat GB2 subunit with three amino acid substitutions in transmembrane domain VI. It was surprising that in contrast to wild-type rat GB2, this mutant subunit was also activated by GS39783 when expressed without GB1. The mutations of both G706T and A708P are necessary and sufficient for activation and identify a key region for the effect of GS39783 in the GB2 transmembrane region. Our data show that mutations of specific amino acids in GB2 can induce agonism in addition to positive modulation and facilitate GB2 activation in the absence of GB1.
Footnotes
-
This work is supported by National Institutes of Mental Health/National Institute on Drug Abuse grant U01-MH60962.
-
ABBREVIATIONS: GPCR, G protein-coupled receptor; CRC, concentration-response curve; ECD, N-terminal extracellular domain; GB1 and GB2, GABAB1 and GABAB2 subunits, respectively; dGB1 and dGB2, D. melanogaster GABAB receptor subunits GABAB1 and GABAB2, respectively; rGB1, rGB2, rat GABAB receptor subunits GABAB1, GABAB2, respectively; GS39783, N,N′-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine; [35S]GTPγS, guanosine 5′-O-(3-[35S]thio)triphosphate; HA, hemagglutinin; HEK, human embryonic kidney; mGluR, metabotropic glutamate receptor; TM, transmembrane; CGP7930, 2,6-di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol; PCR, polymerase chain reaction.
-
↵1 Current affiliation: Institut de Recherches Servier, Croissy/Seine, France.
-
↵2 Current affiliation: The Babraham Institute, Babraham, Cambridge, United Kingdom.
-
↵3 Current affiliation: Lectus Therapeutics Ltd., Babraham, Cambridge, United Kingdom.
- Received June 22, 2006.
- Accepted September 11, 2006.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|